Antengene Corporation shines with groundbreaking cancer research at ASCO 2024

Antengene Corporation Limited, a leading global biopharmaceutical company, is set to make a significant impact at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will be presenting groundbreaking research aimed at advancing the treatment of various types of cancer.

One of the key highlights of Antengene's participation at the event is the presentation of a phase I/II study focusing on the TORC1/2 inhibitor onatasertib in combination with toripalimab for patients with advanced solid tumors, particularly in the cervical cancer cohort. This presentation, scheduled for June 2, 2024, promises to shed light on potential new treatment options for individuals battling this challenging disease.

Another noteworthy presentation will delve into the findings of a first-in-human phase I study of ATG-031, an anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas. Scheduled for June 1-2, 2024, this presentation holds promise for improving outcomes for patients facing these types of cancers.

Furthermore, Antengene will share insights from an open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors. This presentation, part of the Developmental Therapeutics session on June 1-2, 2024, aims to contribute valuable data to the field of oncology and potentially pave the way for novel treatment approaches.

Antengene Corporation's participation in the 2024 ASCO Annual Meeting signifies a commitment to advancing cancer research and improving patient outcomes. By presenting cutting-edge studies and innovative therapies, the company is at the forefront of driving progress in the fight against cancer. The insights shared at this prestigious event have the potential to shape the future of oncology and bring hope to individuals affected by these challenging diseases.